Fighting tuberculosis: Old drugs, new formulations

Expert Opinion on Drug Delivery

Volumn 6, Issue 9, 2009, Pages 977-993

  Blasi, Paolo ^a   Schoubben, Aurélie ^a   Giovagnoli, Stefano ^a   Rossi, Carlo ^a   Ricci, Maurizio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Antitubercular therapy; Liposomes; Macrophage targeting; Microparticles; Nanoparticles; Pulmonary administration; Pulmonary tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GEMIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NANOPARTICLE; OFLOXACIN; POLYESTER; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAPENTINE; ROXITHROMYCIN; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

BIOCOMPATIBILITY; BIODEGRADABILITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SENSITIVITY; EXTRAPULMONARY TUBERCULOSIS; HUMAN; INCIDENCE; LIVER TOXICITY; LUNG CIRCULATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; RECOMMENDED DRUG DOSE; REVIEW; SHORT COURSE THERAPY; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MICROSPHERES; MYCOBACTERIUM TUBERCULOSIS; NANOSPHERES; TUBERCULOSIS;

EID: 70249086623     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903130577     Document Type: Review

References (144)

1. Pinner B, Pinner M. The aetiology of tuberculosis. Dr. Robert Koch. Am Rev Tuberc 1932;25:285-323.
2. English translation of Koch R. Die aetiologie der tuberkulose. Berliner klinische Wochenschrift 1882;19:221-230 with an introduction by Krause AK • The English translation of Koch's original dissertation.
3. Barnes DS. Historical perspective on the etiology of tuberculosis. Microbes Infect 2000;2:431-440
4. Daniel TM. Robert Koch and the pathogenesis of tuberculosis. Int J Tuberc Lung Dis 2005;9:1181-1182
5. Available from: http://nobelprize.org/nobel-prizes/medicine/laureates/ 1905/index.html [Last accessed 12 December 2008]
6. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc Soc Exp Biol Med 1944;55:66-69
7. Schatz A, Waksman SA. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Proc Soc Exp Biol Med 1944;57:244-248
8. Feldman WH, Hinshaw HC. Effects of streptomycin on experimental tuberculosis in guinea pigs. A preliminary report. Proc Staff Meet Mayo Clin 1944;19:593-599
9. Hinshaw HC, Feldman WH. Streptomycin in the treatment of clinical tuberculosis; a preliminary report. Proc Staff Meet Mayo Clin 1945;20:313-318 • The first report on an effective antitubercular drug.
10. Available from: http://nobelprize.org/nobel-prizes/medicine/laureates/ 1952/index.html [Last accessed 12 December 2008]
11. WHO Report 2008, Global tuberculosis control Surveillance, planning, financing. Available from: http://www.who.int/
12. Dye C. Global epidemiology of tuberculosis. Lancet 2006;367:938-940
13. Russell DG. Who puts the tubercle in tuberculosis? Nat Rev Microbiol 2007;5:39-47
14. Jain SK, Lamichhane G, Nimmagadda S, et al. Antibiotic treatment of tuberculosis: Old problems, new solutions. Microbe 2008;3:285-292 (Pubitemid 351845685)
15. World Health Organization 2008, Guidelines for the programmatic management of drug-resistant tuberculosis - Emergency update 2008 •• Complete update of the guidelines for the treatment of drug-resistant tuberculosis
16. Fattorini L, Migliori GB, Cassone A. Extensively drug-resistant (XDR) tuberculosis: an old and new threat. Ann Ist Super Sanità 2007;43:317-319
17. Rom WN, Garay SM. Tuberculosis. Lippincott Williams & Wilkins, Philadelphia, PA. 2004
18. Kaufmann SHE, van Helden P, Rubin E, et al. Handbook of Tuberculosis. Wiley-VCH, 2008
19. Dannenberg AM. Immune mechanisms in the pathogenesis of pulmonary tuberculosis. Rev Infect Dis 1989;11:369-378
20. Rhoades ER, Cooper AM, Orme IM. Chemokine response in mice infected with Mycobacterium tuberculosis. Infect Immunol 1995;63:3871-3877
21. Hunter RL, Olsen M, Jagannath C, et al. Trehalose 6,6′-dimycolate and lipid in the pathogenesis of caseation granulomas of tuberculosis in mice. Am J Pathol 2006;168:1249-1261
22. Matsushima T. Miliary tuberculosis or disseminated tuberculosis. Intern Med 2005;44:687
23. Mert A, Ozaras R. A terminological controversy: Do disseminated and military tuberculosis mean the same? Respiration 2005;72:113
24. Lewis K. Persister cells, dormancy and infectious disease. Nature 2007;5:48-56 (Pubitemid 44942303)
25. Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 2001;55:139-163
26. Gill WP, Harik NS, Whiddon MR, et al. A replication clock for Mycobacterium tuberculosis. Nat Med 2009;15:211-214 •• The first evidence of replication in dormant M. tuberculosis.
27. Lowrie DB. DNA vaccines for therapy of tuberculosis: where are we now? Vaccine 2006;24:1983-1989
28. Nuermberger E, Tyagi S, Williams KN, et al. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Resp Crit Care Med 2005;172:1452-1456 (Pubitemid 43069820)
29. Zhang Y. Advances in the treatment of Tuberculosis. Clin Pharmacol Ther 2007;82:595-600
30. De Souza MVN. Current status and future prospects for new therapies for pulmonary tuberculosis. Curr Opin Pulm Med 2006;12:167-171 (Pubitemid 44350470)
31. Da Silva PA, Ainsa JA. Drugs and drug interaction, In: Palomino JC, Leão SC, Ritacco V, editors, Tuberculosis 2007; from basic science to patient care. 2007. Available from: www.TuberculosisTextbook.com [Last accessed 25 March 2009]
32. Saravia JC, Appleton SC, Rich ML, et al. Retreatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis 2005;9:421-429
33. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004;363:474-481 (Pubitemid 38210067)
34. De Kantor IN, Barrera L. Susceptibility tests to second line drugs and re-treatment of tuberculosis: revisiting early experiences. Medicina 2007;67:231-237 (Pubitemid 47064299)
35. Gruppo V, Johnson CM, Marietta KS, et al. Rapid microbiologic and pharmacologic evaluation of experimental compounds against mycobacterium tuberculosis. Antimicrob Agents Chemother 2006;50:1245-1250
36. Iona E, Giannoni F, Pardini M, et al. Metronidazole plus rifampin sterilizes long-term dormant mycobacterium tuberculosis. Antimicrob Agents Chemother 2007;51:1537-1540 (Pubitemid 46586847)
37. Fattorini L, Tan D, Iona E, et al. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant mycobacterium tuberculosis infection in BALB/c Mice. Antimicrob Agents Chemother 2003;47:360-362 (Pubitemid 36070385)
38. Col BNBM, Prasad A. Study on comparative efficacy of anti tubercular chemoprophylaxis with 2 different regimens: 2 months of rifampicin and pyrazinamide and 6 months of daily isoniazid and rifampicin in HIV infected tuberculin reactors. Lung India 2006;23:64-69
39. Weiner M, Bock N, Peloquin CA, et al. Pharmacokinetics of rifapentine at 600, 900, and 1.200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 2004;169:1191-1197 (Pubitemid 38680395)
40. Rosenthal IM, Zhang M, Williams KN, et al. Daily Dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:1931-1939
41. Cole ST, Alzari PM. Towards new tuberculosis drugs. Biochem Soc Trans 2007;35:1315-1324
42. Gohel MC, Sarvaiya KG. A novel solid dosage form of rifampicin and isoniazid with improved functionality. AAPS PharmSciTech 2007;8:68
43. Prabakaran D, Singh P, Jaganathan KS, et al. Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs. J Control Release 2004;95:239-248 (Pubitemid 38232673)
44. Hopewell PC, Pai M, Maher D, et al. International standards for tuberculosis care. Lancet Infect Dis 2006;6:710-725
45. Duncan K, Barry CE III. Prospects for new antitubercular drugs. Curr Opin Microbiol 2004;7:460-465
46. Pandey R, Khuller GH. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 2005;55:430-435 (Pubitemid 40542580)
47. Birnbaum DT, Brannon-Peppas L. Microparticle drug delivery systems, In: Brown DM, editor, Drug delivery systems in cancer therapy. Humana Press, New Jersey; 2004. p. 117-135
48. Ricci M, Giovagnoli S, Blasi P, et al. Development of liposomal capreomycin sulfate formulations: Effects of formulation variables on peptide encapsulation. Int J Pharm 2006;311:172-181 (Pubitemid 43319216)
49. Giovagnoli S, Blasi P, Schoubben A, et al. Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery. Int J Pharm 2007;333:103-111 • A simple way to prepare large porous microparticles. (Pubitemid 46283276)
50. Hurley L, Andersen BR. Biodegradable implants from poly-(alpha-hydroxy acid) polymers for isoniazid delivery. Int J Tuberc Lung Dis 1999;3:1015-1024
51. Chaubal M. Polylactides/glycolides-excipients for injectable drug delivery and beyond. Drug Deliv Technol 2002;5:34-36
52. Dutt M, Khuller GK. Sustained release of isoniazid from a single injectable dose of poly(DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agents 2001;17:115-122 (Pubitemid 32101566)
53. Dutt M, Khuller GK. Therapeutic efficacy of poly(DL-lactide-co-glycolide) -encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 2001;45:363-366 (Pubitemid 32039149)
54. Dutt M, Khuller GK. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly(DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother 2001;47:829-835 (Pubitemid 32519831)
55. Barrow ELW, Winchester GA, Staas JK, et al. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob Agents Chemother 1998;42:2682-2689
56. Quenelle DC, Staas JK, Winchester GA, et al. Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother 1999;43:1144-1151
57. Nakaoka R, Tabata Y, Ikada Y. Adjuvants effect of biodegradable poly(DL-lactic acid) granules capable for antigen release following intraperitoneal injection. Vaccine 1996;14:1671-1676 (Pubitemid 27041921)
58. Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng 2007;96:203-209
59. Tsai M, Lu Z, Wang J, et al. Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm Res 2007;24:1691-1701 (Pubitemid 47206619)
60. Quenelle DC, Winchester GA, Staas JK, et al. Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid. Antimicrob Agents Chemother 2001;45:1637-1644
61. O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 2000;17:955-961 (Pubitemid 30736598)
62. Garcia-Contreras L, Sethuraman V, Kazantseva M, et al. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J Antimicrob Chemother 2006;58:980-986
63. Suarez S, O'Hara P, Kazantseva M, et al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother 2001;48:431-434 (Pubitemid 32898818)
64. Hirota K, Hasegawa T, Hinata H, et al. Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J Control Release 2007;119:69-76 • Systematic analysis of the most important parameters affecting particle phagocytosis. (Pubitemid 46561547)
65. Zhou H, Zhang Y, Biggs DL, et al. Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages. J Control Release 2005;107:288-299 (Pubitemid 41316291)
66. Sharma R, Saxena D, Dwivedi AK, et al. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001;18:1405-1410 (Pubitemid 32977245)
67. Muttil P, Kaur J, Kumar K, et al. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci 2007;32:140-150 (Pubitemid 47285721)
68. Rossi C, Fardella G, Chiappini I, et al. UV spectroscopy and reverse-phase HPLC as novel methods to determine capreomycin of liposomal formulations. J Pharm Biomed Anal 2004;36:249-255 (Pubitemid 39371069)
69. Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 2007;51:2830-2836 • An interesting preclinical study in a guinea-pig model. (Pubitemid 47206218)
70. Fiegel J, Garcia-Contreras L, Thomas M, et al. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res 2008;25:805-811 • An interesting preclinical study in a guinea-pig model. (Pubitemid 351661830)
71. Giovagnoli S, Songara D, Blasi P, et al. Preparation and characterization of respirable biodegradable microspheres for capreomycin pulmonary delivery. 12th International Pharmaceutical Technology Symposium, Istanbul, Turkey, 12-15 September, 2004
72. Abdellaziz BJ, Chen D, Eskew ML, et al. Large porous particles for sustained release from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res 1999;16:555-561 (Pubitemid 29191302)
73. Edwards DA, Hanes J, Caponnetti G, et al. Large porous particle for pulmonary drug delivery. Science 1997;276:1868-1871 •• The first report on the application of large porous particles for inhalation. (Pubitemid 27336410)
74. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large porous inhaled particles. J Appl Physiol 1998;85:379-385 (Pubitemid 28365799)
75. Tsapis N, Bennet D, Jackson B, et al. Trojan particles: large porous carriers of nanoparticles for drug delivery. PNAS 2002;99:12001-12005 • An elegant way to combine the advantages of nanoparticles and microparticles.
76. Quintanar-Guerrero D, Alléman E, Fessi H, et al. Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides. Pharm Res 1997;14:119-127 (Pubitemid 27146352)
77. Schoubben A. Strategies for native protein and peptide delivery. Doctorate thesis discussed on February 8th 2008
78. Sharma R, Muttil P, Yadav AB, et al. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J Antimicrob Chemother 2007;59:499-506 (Pubitemid 47073457)
79. Lucinda-Silva RM, Evangelista RC. Microspheres of alginate-chitosan containing isoniazid. J Microencapsul 2003;20:145-152
80. Ain Q, Sharma S, Garg SK, et al. Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s). Int J Pharm 2002;239:37-46 (Pubitemid 34615793)
81. Ain Q, Sharma S, Khuller GK. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. Antimicrob Agents Chemother 2003;47:3005-3007 (Pubitemid 37040288)
82. Ain Q, Sharma S, Khuller GK, et al. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother 2003;51:931-938 (Pubitemid 36503426)
83. Pandey R, Khuller GK. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother 2004;53:635-640 (Pubitemid 38499780)
84. Khuller GK, Kapur M, Sharma S. Liposome technology for drug delivery against Mycobacterial infections. Curr Pharm Design 2004;10:3263-3274 (Pubitemid 39276614)
85. Vladimirsky MA, Ladigina GA. Antibacterial activity of liposome-entrapped streptomycin in mice infected with Mycobacterium tuberculosis. Biomed Pharmacother 1982;36:375-377
86. Gaspar MM, Cruz A, Penha AF, et al. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int J Antimicrob Agents 2008;31:37-45 (Pubitemid 350245738)
87. Ladigina GA, Vladimirsky MA. The comparative pharmacokinetics of 3H-dihydrostreptomycin in solution and liposomal form in normal and M. tuberculosis infected mice. Biomed Pharmacother 1986;40:416-420
88. Orozco LC, Forero M, Wasserman M, et al. Distribution of liposomes in tuberculous mice. Tubercle 1990;71:209-214
89. Le Conte P, Le Gallou F, Potel G, et al. Pharmaokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model. Antimicrob Agents Chemother 1994;38:2695-2701 (Pubitemid 24374423)
90. Giovagnoli S, Blasi P, Vescovi C, et al. Unilamellar vesicles as potential capreomycin sulfate carriers: preparation and physicochemical characterization. AAPS PharmSciTech 2003;4:69 (Pubitemid 41086179)
91. Ricci M, Giovagnoli S, Blasi P, et al. Development of liposomal capreomycin sulfate formulations: Effects of formulation variables on peptide encapsulation. Int J Pharm 2006;311:172-181 (Pubitemid 43319216)
92. Giovagnoli S, Ricci M, Blasi P, et al. Development of liposomal capreomycin sulfate formulations: mathematical modeling of peptide encapsulation. AAPS Annual Meeting and Exposition, 6-10 November 2005, Nashville, TN, USA
93. Giovagnoli S, Blasi P, Schoubben A, et al. Capreomycin sulfate respirable liposome formulations for antitubercular therapy. 33rd Annual Meeting and Exposition of the Controlled Release Society, 22-26 July 2006, Vienna, Austria
94. Musumeci T, Ventura CA, Giannone I, et al. Development of a liposome formulation for D-cycloserine local delivery. J Liposome Res 2008;18:211-224
95. Hood WF, Compton RP, Monahan JB. D-cycloserine: a ligand for the N-methyl-D-aspartate-coupled glycine receptor has partial agonist characteristics. Neurosci Lett 1989;98:1167-1171
96. Orozco LC, Quintana FO, Beltran RM, et al. The use of rifampicin and isoniazid entrapped in liposomes for the treatment of murine tuberculosis. Tuberculosis 1986;67:91-97 (Pubitemid 16080226)
97. Adams LB, Sinha I, Franzblau SG, et al. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob Agents Chemother 1999;43:1638-1643 (Pubitemid 29331240)
98. Deol P, Khuller GK. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta 1997;1334:161-172 (Pubitemid 27117518)
99. Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampicin encapsulated in lung specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 1997;41:1211-1214 (Pubitemid 27231415)
100. Labana S, Pandey R, Sharma S, et al. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int J Antimicrob Agents 2002;20:301-304
101. Agrawal AK, Gupta CM. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv Drug Deliv Rev 2000;41:135-146
102. Agarwal A, Kandpal H, Gupta HP, et al. Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice. Antimicrob Agents Chemother 1994;38:588-593 (Pubitemid 24072253)
103. Gilbert BE. Liposomal aerosols in the management of pulmonary infections. J Aerosol Med 1996;9:111-122
104. Conley J, Yang H, Wilson T, et al. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother 1997;41:1288-1292 (Pubitemid 27231428)
105. Vyas SP, Quraishi S, Gupta S, et al. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 2005;296:12-25 (Pubitemid 40693368)
106. Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993;328:861-868
107. Pandey R, Sharma S, Khuller GK. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicob Agents 2004;24:93-94 (Pubitemid 38844571)
108. Vyas SP, Kannan ME, Jain S, et al. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophage. Int J Pharm 2004;269:37-49 (Pubitemid 38035210)
109. Fielding RM, Lewis RO, Moon-McDermott L. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome®). Pharm Res 1998;15:1775-1781 (Pubitemid 28524591)
110. Whitehead TC, Lovering AM, Cropley IM, et al. Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis 1998;17:794-797 •• The first case report on the use of MiKasome in a multi-drug resistant tuberculosis patient.
111. Donald PR, Sirgel FA, Venter A, et al. The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis. J Antimicrob Chemother 2001;48:877-880 •• A study of MiKasome efficacy in seven patients. (Pubitemid 33735324)
112. Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006;23:1417-1450 • An extensive review on the application of nanotechnology. (Pubitemid 43993807)
113. Fielding RM, Moon-McDermott L, Lewis RO, et al. Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey. Antimicrob Agents Chemother 1999;43:503-509 •• One example of preclinical studies in non-human primates.
114. Dhillon J, Fielding R, Adler-Moore J, et al. The activity of low-clearance amikacin in experimental murine tubercuosis. J Antimicrob Chemother 2001;48:869-876 (Pubitemid 33735323)
115. Ricci M, Blasi P, Giovagnoli S, et al. Leucinostatin-A loaded nanospheres: characterization and in vivo toxicity and efficacy evaluation. Int J Pharm 2004;275:61-72 (Pubitemid 38481520)
116. Anisimova YV, Gelperina SI, Peloquin CA, et al. Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages. J Nanoparticle Res 2000;2:165-171
117. Pandey R, Zahoor A, Sharma S, et al. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 2003;83:373-378 (Pubitemid 37464042)
118. Sharma A, Pandey R, Sharma S, et al. Chemotherapeutic efficacy of poly (dl-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents 2004;24:599-604 (Pubitemid 39536116)
119. Pandey R, Sharma A, Zahoor A, et al. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981-986 (Pubitemid 38008419)
120. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004;54:761-766 (Pubitemid 39386728)
121. Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs. Drug Deliv 2006;13:287-294 (Pubitemid 43739140)
122. Jani P, Halbert GW, Langridge J, et al. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1989;41:809-812 (Pubitemid 20112141)
123. Jani P, Halbert GW, Langridge J, et al. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 1990;42:821-826
124. Araujo L, Sheppard M, Löbenberg R, et al. Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: modification of the body distribution after suspension in surfactant solutions and in oil vehicles. Int J Pharm 1999;176:209-224 (Pubitemid 29048305)
125. Löbenberg R, Araujo L, Kreuter J. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur J Pharm Biopharm 1997;44:127-132 (Pubitemid 28539146)
126. Pandey R, Khuller GK. Subcuteneous nanoparticle-base antitubercular chemotherapy in an experimental model. J Antimicrob Chemother 2004;54:266-268 (Pubitemid 39029006)
127. Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005;26:298-303 (Pubitemid 41338657)
128. Müller RH. Lipid nanoparticles: recent advances. Adv Drug Deliv Rev 2007;59:375-376
129. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-177 (Pubitemid 30326695)
130. Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis 2005;85:415-420 (Pubitemid 41617396)
131. Yang S, Zhu J, Lu Y, et al. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999;16:751-757 (Pubitemid 29227107)
132. Hanafy A, Spahn-Langguth H, Vergnault G, et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev 2007;59:419-426 (Pubitemid 47260709)
133. Hu L, Tang X, Cui F. Solid Lipid Nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol 2004;56:1527-1535
134. Lamprecht A, Saumet JL, Roux J, et al. Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment. Int J Pharm 2004;278:407-414 (Pubitemid 38759512)
135. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005;85:227-234 (Pubitemid 40805619)
136. Müller RH, Olbrich C. Solid lipid nanoparticles: phagocytic uptake, in vitro cytotoxicity and in vivo biodegradation. Drugs Made Ger 1999;42:75-79 (Pubitemid 29458784)
137. Weyhers H, Ehlers S, Hahn H, et al. Solid lipid nanoparticles (SLN) effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie 2006;61:539-544 (Pubitemid 43989132)
138. Aly S, Lin PL, Ray SM, et al. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J Pathol 2006;210:298-305 (Pubitemid 44660508)
139. Tsai MC, Chakravarty S, Zhu G, et al. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 2006;8:218-232 (Pubitemid 43356045)
140. Via LE, Lin PL, Ray SM, et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits and nonhuman primates. Infect Immun 2008;76:2333-2340
141. Available from: http://www.stoptb.org/ [Last accessed 26 March 2009]
142. Available from: http://www.medicineinneed.org/ [Last accessed 26 March 2009]
143. Wong YL, Sampson S, Germishuizen WA, et al. Drying a tuberculosis vaccine without freezing. PNAS 2007;104:2591-2595 • A new method to produce an inhalable and highly viable BCG vaccine. (Pubitemid 46327924)
144. Garcia-Contreras L, Wong YL, Muttil P, et al. Immunization by bacterial aerosol. PNAS 2008;105:4656-4660 • An in vivo study demonstrating the efficacy of an inhalable BCG vaccine in guinea-pigs.